Zhonghui Bio’s quadrivalent influenza virus subunit vaccine marketing application approved

September 4, 2025 Source: drugdu 214

On September 3, Zhonghui Bio announced that the National Medical Products Administration has approved the company's quadrivalent influenza vaccine　　for people aged 6-35 months.The new drug application for the influenza virus subunit vaccine was filed. The announcement shows that this vaccine has become the first and only full-dose quadrivalent influenza virus subunit vaccine approved for marketing in China.
https://finance.eastmoney.com/a/202509033503778045.html